COVID-19

The Cardiovascular Impact of COVID-19

The COVID-19 impact to the heart is far more prevalent than we recognize today. In fact, a study published in 2020 shows 78% of COVID-19 patients had some form of cardiac involvement following recovery, and 60% had ongoing myocardial inflammation.1 The majority of patients had recovered at home, and none had prior known cardiovascular issues. As a result, patients with past COVID diagnoses–especially those with preexisting heart conditions–may be at a higher risk of developing worsening cardiovascular complications, such as myocarditis and pericarditis.2 This highlights the need for highly sensitive, rapid and safe diagnostics to monitor and manage the potential long-term effects of COVID-19 on the heart.

MyoStrain provides a sensitive, accurate and COVID-safe heart health assessment for patients recovering from COVID-19. Complete in under 10 minutes, MyoStrain gives clinicians novel cardiac insights to detect the early cardiac effects of COVID-19, enabling opportunities to monitor changes in heart health over time and optimize treatment for improved outcomes and quality of life.

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019

Cardio-Oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
August 31, 2019
Abstract at ESC Congress 2019